Roche's Prasinezumab Misses Goal in Parkinson's Disease Study

Roche (RHHBY) announced data from the phase IIb PADOVA study which evaluated its investigational monoclonal antibody, prasinezumab, for treating people with early-stage Parkinson’s disease.The double-blind PADOVA study evaluated the safety and efficacy of prasinezumab versus placebo in 586 randomized patients with early-stage Parkinson’s disease who were on stable symptomatic treatment.The study missed the primary endpoint.Data from the study showed that treatment with prasinezumab demonstrated potential cl ...